Functional invadopodia formation through stabilization of the PDPN transcript by IMP-3 and cancer-stromal crosstalk

Young Sun Hwang1, Zhang Xianglan, Kwang-Kyun Park

  • 1Oral Cancer Research Institute, Yonsei University College of Dentistry, Republic of Korea. peroxiredoxin@yuhs.ac

Carcinogenesis
|August 4, 2012
PubMed

Insights

Insulin-like growth factor-II mRNA-binding protein-3 (IMP-3) regulates podoplanin (PDPN) expression, impacting oral squamous cell carcinoma invasion. Targeting the IMP-3-PDPN axis offers a potential therapeutic strategy for metastatic cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Insulin-like growth factor-II mRNA-binding protein-3 (IMP-3) depletion inhibits invadopodia and extracellular matrix degradation in oral squamous cell carcinoma (OSCC).
  • The precise molecular mechanisms linking IMP-3 to cancer invasion require further elucidation.

Purpose of the Study:

  • To investigate the role of IMP-3 in regulating podoplanin (PDPN) expression and its subsequent impact on OSCC invasion.
  • To explore the therapeutic potential of targeting the IMP-3-PDPN axis in metastatic cancers.

Main Methods:

  • RNA in situ hybridization and luciferase reporter assays to assess PDPN gene expression regulation by IMP-3.
  • Xenograft models to evaluate the in vivo effects of PDPN depletion on tumor growth and invasion.
  • Immunohistochemical dual staining in patient samples to analyze IMP-3 and PDPN co-expression.

Main Results:

  • IMP-3 depletion downregulates PDPN levels, reducing extracellular matrix degradation and tumor invasion.
  • Transforming growth factor beta 1 and interleukin-1 beta signaling pathways are involved in regulating PDPN expression.
  • IMP-3 and PDPN expression positively correlate with lymph node metastasis in OSCC patients.

Conclusions:

  • The IMP-3-PDPN axis is a critical regulator of OSCC invasion and metastasis.
  • Targeting IMP-3 or PDPN may represent a novel therapeutic strategy for combating metastatic oral squamous cell carcinoma.

Related Concept Videos

Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...